Editas Medicine Inc Total Assets
Editas Medicine Inc total assets. Based on the latest financial reports, Editas Medicine Inc (EDIT) holds total assets worth $237.36 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see EDIT stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Editas Medicine Inc (2013–2025)
Total assets of Editas Medicine Inc from 2013 to 2025. This chart illustrates how Editas Medicine Inc's total assets have evolved over time, based on quarterly financial data. See EDIT live share price for real-time trading data and today's change.
Editas Medicine Inc - Asset Composition Analysis
Editas Medicine Inc Total Assets Breakdown (December 2025)
Editas Medicine Inc total assets breakdown as of December 2025. Editas Medicine Inc's total assets of $237.36 Million consist of 87.9% current assets and 12.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.6% |
| Accounts Receivable | $15.18 Million | 8.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Editas Medicine Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Editas Medicine Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Editas Medicine Inc's current assets represent 87.9% of total assets in 2025, an increase from 84.2% in 2013.
- Cash Position: Cash and equivalents constituted 78.6% of total assets in 2025, down from 81.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 8.1% of total assets.
Editas Medicine Inc Competitors by Total Assets
Key competitors of Editas Medicine Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Editas Medicine Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.19 | 2.77 | 11.15 |
| Quick Ratio | 3.19 | 2.77 | 11.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $149.63 Million | $116.86 Million | $516.70 Million |
Editas Medicine Inc - Advanced Valuation Insights
This section examines the relationship between Editas Medicine Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.86 |
| Latest Market Cap to Assets Ratio | 2.20 |
| Asset Growth Rate (YoY) | -45.4% |
| Total Assets | $186.53 Million |
| Market Capitalization | $410.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Editas Medicine Inc's assets at a significant premium (2.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Editas Medicine Inc's assets decreased by 45.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Editas Medicine Inc (2013–2025)
The table below shows the annual total assets of Editas Medicine Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $186.53 Million | -45.39% |
| 2024-12-31 | $341.59 Million | -31.57% |
| 2023-12-31 | $499.15 Million | -2.95% |
| 2022-12-31 | $514.32 Million | -24.08% |
| 2021-12-31 | $677.48 Million | +18.32% |
| 2020-12-31 | $572.60 Million | +12.52% |
| 2019-12-31 | $508.88 Million | +21.05% |
| 2018-12-31 | $420.39 Million | +12.63% |
| 2017-12-31 | $373.26 Million | +62.87% |
| 2016-12-31 | $229.18 Million | +53.44% |
| 2015-12-31 | $149.36 Million | +1125.49% |
| 2014-12-31 | $12.19 Million | +391.25% |
| 2013-12-31 | $2.48 Million | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more